Summary & Overview
HCPCS Level II J2060: Lorazepam Injection, 2 mg
HCPCS Level II code J2060 identifies the injection of lorazepam, 2 mg, a commonly used parenteral benzodiazepine for sedation, anxiety management, and procedural indications. Nationally, accurate coding for injectable psychotropic medications like lorazepam affects billing, care coordination, and controlled-substance oversight across inpatient, outpatient, and emergency settings. This code is relevant for clinicians, coders, and payers handling claims for procedural sedation, acute agitation, or short-term anxiolysis.
Key payers reviewed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J2060 represents clinically and operationally, typical sites of service where it is used, and which major payers commonly process claims for this injection. The publication outlines benchmark elements and policy considerations that affect coverage and billing for injectable lorazepam, including payer-specific coverage patterns and reimbursement practices where available. Practical context is provided for coding accuracy, claim adjudication, and documentation expectations. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J2060 denotes an injection of lorazepam, 2 mg. This code represents a medication administration service for the benzodiazepine lorazepam at a 2 mg dose.
-
Service type: Medication injection
-
Typical site of service: Ambulatory clinic, hospital inpatient or outpatient setting, emergency department, or other facility-based settings where parenteral medication administration occurs
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an emergency department, ambulatory surgery center, or behavioral health unit with acute severe agitation, status epilepticus, or severe anxiety requiring parenteral benzodiazepine therapy. The clinician (emergency physician, hospitalist, anesthesiologist, or psychiatrist) orders J2060 for administration of lorazepam 2 mg via intramuscular or slow intravenous injection when rapid onset sedation or anticonvulsant effect is clinically indicated. The workflow includes assessment of airway and breathing, informed consent when possible, medication reconciliation to avoid drug interactions (notably opioids and other CNS depressants), preparation of lorazepam 2 mg vial or prefilled syringe, documentation of dose, route, time, and patient response, and appropriate post-administration monitoring for respiratory depression, hypotension, and sedation level. In procedural sedation or perioperative settings, J2060 may be used as premedication prior to induction or as adjunct for anxiolysis; anesthesia personnel document monitoring and recovery. In outpatient infusion or clinic-based injection settings, nursing documents vital signs pre- and post-injection and communicates adverse effects to the prescribing provider.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure |